Researchers have reported encouraging results from preclinical studies of SOL-257, an experimental gene therapy designed to address underlying disease mechanisms in ALS. In two mouse models of ALS, the therapy improved motor function and extended survival, suggesting it may help slow disease progression rather than just manage symptoms. These findings
SOLA Biosciences has shared new preclinical proof-of-concept data for SOL-257, an experimental gene therapy aimed at addressing a key biological driver of ALS. The therapy is designed to reduce the harmful effects of misfolded TDP-43, a protein linked to nerve cell damage in many people with the disease. By targeting
